Vosevi
Active Ingredient(s): Sofosbuvir + Velpatasvir + VoxilaprevirFDA Approved: * July 18, 2017
Pharm Company: * GILEAD SCIENCES INC
Category: Hepatitis
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Vosevi Overview
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[2] On 18 July 2017, Vosevi was approved by Food and drug administration.[3] References ^ "voxilaprevir_msds"..mw-parser-output cite.citation{...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Voxilaprevir
Recent Vosevi Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Sofosbuvir + Velpatasvir + Voxilaprevir
- Tablet: 400mg + 100mg + 100mg
NDC Database Records for Vosevi: (1 result)
Sorted by National Drug Code- 61958-2401 Vosevi Oral Tablet, Film Coated by Gilead Sciences, Inc.
Drugs with one or more similar ingredients: (7 results)
- SOFOSBUVIR + VELPATASVIR + VOXILAPREVIR
- EPCLUSA Sofosbuvir + Velpatasvir9 discussions
- HARVONI Ledipasvir + Sofosbuvir59 discussions
- LEDIPASVIR + SOFOSBUVIR 1 discussion
- SOFOSBUVIR 1 discussion
- SOFOSBUVIR + VELPATASVIR 1 discussion
- SOVALDI Sofosbuvir17 discussions